Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Medical Hypotheses

• Publication date

  2017-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.mehy.2017.03.016PMID 28478831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How to screen NAFLD patients for diabetes?

  2016cited by this paper
• Entry inhibitors: New advances in HCV treatment

  2016cited by this paper
• What are the pros and cons of the use of host-targeted agents against hepatitis C?

  2014cited by this paper
• Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

  2014cited by this paper
• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.

  2012cited by this paper
• Hepatitis C RNA clearance after treatment with ezetimibe

  2012cited by this paper
• Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

  2012cited by this paper
• Cholesterol, an essential molecule: diverse roles involving cytochrome P450 enzymes.

  2012cited by this paper
• Cholesterol uptake and hepatitis C virus entry.

  2012cited by this paper
• Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor

  2011cited by this paper
• Genetic variant of the scavenger receptor BI in humans.

  2011cited by this paper
• Regulation of cholesterol homeostasis

  2011cited by this paper
• The N-terminal Domain of NPC1L1 Protein Binds Cholesterol and Plays Essential Roles in Cholesterol Uptake*

  2011cited by this paper
• EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

  2011cited by this paper
• Transmission of HCV in HIV-positive populations.

  2011cited by this paper
• Deletion of the High-Density Lipoprotein Receptor Scavenger Receptor BI in Mice Modulates Thrombosis Susceptibility and Indirectly Affects Platelet Function by Elevation of Plasma Free Cholesterol

  2011cited by this paper
• MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.

  2011cited by this paper
• Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

  2011cited by this paper
• Liver transplantation and hepatitis C.

  2011cited by this paper
• Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.

  2011cited by this paper
• Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection

  2010cited by this paper
• Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly[S]

  2010cited by this paper
• Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake

  2010cited by this paper
• Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor.

  2009cited by this paper
• The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients

  2009cited by this paper
• Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials

  2009cited by this paper
• A functional genomic screen identifies cellular cofactors of hepatitis C virus replication.

  2009cited by this paper
• The global burden of hepatitis C

  2009cited by this paper
• Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

  2009cited by this paper
• Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia

  2009cited by this paper
• Host neutralizing responses and pathogenesis of hepatitis C virus infection

  2008cited by this paper
• Ezetimibe prevents cholesterol gallstone formation in mice

  2008cited by this paper
• Physiology of bile secretion.

  2008cited by this paper
• The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.

  2008cited by this paper
• Tight Junction Proteins Claudin-1 and Occludin Control Hepatitis C Virus Entry and Are Downregulated during Infection To Prevent Superinfection

  2008cited by this paper
• Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81

  2007cited by this paper
• Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

  2007cited by this paper
• Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice.

  2007cited by this paper
• Ezetimibe‐associated adverse effects: what the clinician needs to know

  2007cited by this paper
• Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.

  2007cited by this paper
• Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis

  2006cited by this paper
• Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients

  2006cited by this paper
• Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan SulfateInteraction

  2006cited by this paper
• Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry

  2006cited by this paper
• Ezetimibe

  2005cited by this paper
• Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

  2005cited by this paper
• Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.

  2005cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Association of hepatitis C virus in human sera with β-lipoprotein

  2004cited by this paper
• C-type Lectins L-SIGN and DC-SIGN Capture and Transmit Infectious Hepatitis C Virus Pseudotype Particles*

  2004cited by this paper
• CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection

  2004cited by this paper
• Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.

  2003cited by this paper
• Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR

  2003cited by this paper
• Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

  2003cited by this paper
• Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate*

  2003cited by this paper
• Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

  2003cited by this paper
• Hepatitis C virus kinetics during and immediately after liver transplantation

  2002cited by this paper
• The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Hepatitis C virus replication in mice with chimeric human livers

  2001cited by this paper
• Detection of hepatitis C virus in the bile and bile duct epithelial cells of hepatitis C virus–Infected patients

  2001cited by this paper
• Detection and Quantitation of Hepatitis C Virus RNA in Feces of Chronically Infected Individuals

  2000cited by this paper
• Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry.

  1999cited by this paper
• Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

  1999cited by this paper
• Binding of hepatitis C virus to CD81.

  1998cited by this paper
• Detection of hepatitis C virus RNA in bile.

  1997cited by this paper
• Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions

  1996cited by this paper
• Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor

  1996cited by this paper
• [Detection of HCV-RNA in saliva and stool of patients with HCV infection].

  1995cited by this paper
• Recurrent and acquired hepatitis C viral infection in liver transplant recipients.

  1992cited by this paper
• Association of hepatitis C virus in human sera with beta-lipoprotein.

  1992cited by this paper

• Host directed therapies: COVID-19 and beyond

  2021cites this paper